Annual CFI
$55.78 M
+$88.33 M+271.34%
31 December 2023
Summary:
Travere Therapeutics annual cash flow from investing activities is currently $55.78 million, with the most recent change of +$88.33 million (+271.34%) on 31 December 2023. During the last 3 years, it has risen by +$117.10 million (+190.95%). TVTX annual CFI is now at all-time high.TVTX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$46.13 M
+$17.52 M+61.22%
30 September 2024
Summary:
Travere Therapeutics quarterly cash flow from investing activities is currently $46.13 million, with the most recent change of +$17.52 million (+61.22%) on 30 September 2024. Over the past year, it has dropped by -$87.19 million (-65.40%). TVTX quarterly CFI is now -65.40% below its all-time high of $133.32 million, reached on 30 September 2023.TVTX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$162.68 M
-$87.19 M-34.89%
30 September 2024
Summary:
Travere Therapeutics TTM cash flow from investing activities is currently $162.68 million, with the most recent change of -$87.19 million (-34.89%) on 30 September 2024. Over the past year, it has increased by +$126.66 million (+351.59%). TVTX TTM CFI is now -34.89% below its all-time high of $249.88 million, reached on 30 June 2024.TVTX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TVTX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +271.3% | -65.4% | +351.6% |
| 3 y3 years | +190.9% | +41.8% | +160.1% |
| 5 y5 years | +127.4% | +933.1% | +633.1% |
TVTX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +140.5% | -65.4% | +218.0% | -34.9% | +160.1% |
| 5 y | 5 years | at high | +127.4% | -65.4% | +136.8% | -34.9% | +147.0% |
| alltime | all time | at high | +127.4% | -65.4% | +128.6% | -34.9% | +147.0% |
Travere Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $46.13 M(+61.2%) | $162.68 M(-34.9%) |
| June 2024 | - | $28.61 M(-72.7%) | $249.88 M(+26.4%) |
| Mar 2024 | - | $104.90 M(-718.9%) | $197.71 M(+254.5%) |
| Dec 2023 | $55.78 M(-271.3%) | -$16.95 M(-112.7%) | $55.78 M(+54.8%) |
| Sept 2023 | - | $133.32 M(-666.0%) | $36.02 M(-141.3%) |
| June 2023 | - | -$23.55 M(-36.4%) | -$87.21 M(-15.1%) |
| Mar 2023 | - | -$37.04 M(+0.9%) | -$102.76 M(+215.7%) |
| Dec 2022 | -$32.55 M(-76.3%) | -$36.70 M(-464.1%) | -$32.55 M(-382.6%) |
| Sept 2022 | - | $10.08 M(-125.8%) | $11.52 M(-66.1%) |
| June 2022 | - | -$39.10 M(-217.9%) | $33.96 M(+2621.1%) |
| Mar 2022 | - | $33.16 M(+350.0%) | $1.25 M(-100.9%) |
| Dec 2021 | -$137.62 M(+124.4%) | $7.37 M(-77.3%) | -$137.62 M(-49.1%) |
| Sept 2021 | - | $32.52 M(-145.3%) | -$270.50 M(-21.9%) |
| June 2021 | - | -$71.81 M(-32.1%) | -$346.19 M(+67.6%) |
| Mar 2021 | - | -$105.71 M(-15.8%) | -$206.58 M(+236.9%) |
| Dec 2020 | -$61.33 M(-408.7%) | -$125.51 M(+190.7%) | -$61.33 M(-193.3%) |
| Sept 2020 | - | -$43.17 M(-163.7%) | $65.76 M(-42.0%) |
| June 2020 | - | $67.80 M(+71.4%) | $113.40 M(+60.1%) |
| Mar 2020 | - | $39.55 M(+2403.2%) | $70.83 M(+256.6%) |
| Dec 2019 | $19.86 M(-109.8%) | $1.58 M(-64.6%) | $19.86 M(-165.1%) |
| Sept 2019 | - | $4.46 M(-82.3%) | -$30.52 M(-84.5%) |
| June 2019 | - | $25.23 M(-321.1%) | -$196.53 M(+1.4%) |
| Mar 2019 | - | -$11.41 M(-76.6%) | -$193.85 M(-4.6%) |
| Dec 2018 | -$203.29 M | -$48.80 M(-69.8%) | -$203.29 M(+31.5%) |
| Sept 2018 | - | -$161.54 M(-678.9%) | -$154.59 M(-3344.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2018 | - | $27.91 M(-233.8%) | $4.76 M(-76.9%) |
| Mar 2018 | - | -$20.85 M(>+9900.0%) | $20.63 M(-54.8%) |
| Dec 2017 | $45.60 M(+339.7%) | -$103.00 K(-95.3%) | $45.60 M(-40.1%) |
| Sept 2017 | - | -$2.19 M(-105.0%) | $76.17 M(+5.3%) |
| June 2017 | - | $43.77 M(+961.0%) | $72.31 M(+198.2%) |
| Mar 2017 | - | $4.13 M(-86.5%) | $24.25 M(+133.9%) |
| Dec 2016 | $10.37 M(-112.9%) | $30.47 M(-603.5%) | $10.37 M(-108.6%) |
| Sept 2016 | - | -$6.05 M(+41.0%) | -$120.56 M(+93.6%) |
| June 2016 | - | -$4.29 M(-56.0%) | -$62.29 M(+4.6%) |
| Mar 2016 | - | -$9.76 M(-90.3%) | -$59.55 M(-26.1%) |
| Dec 2015 | -$80.60 M(+116.3%) | -$100.46 M(-292.4%) | -$80.60 M(-469.2%) |
| Sept 2015 | - | $52.22 M(-3462.7%) | $21.83 M(-167.3%) |
| June 2015 | - | -$1.55 M(-95.0%) | -$32.46 M(-12.2%) |
| Mar 2015 | - | -$30.81 M(-1664.0%) | -$36.96 M(-0.8%) |
| Dec 2014 | -$37.26 M(+589.3%) | $1.97 M(-195.5%) | -$37.26 M(-1.9%) |
| Sept 2014 | - | -$2.06 M(-65.9%) | -$37.97 M(-8.0%) |
| June 2014 | - | -$6.06 M(-80.5%) | -$41.26 M(+17.2%) |
| Mar 2014 | - | -$31.11 M(-2560.7%) | -$35.21 M(+551.4%) |
| Dec 2013 | -$5.41 M(+218.1%) | $1.26 M(-123.6%) | -$5.41 M(-19.0%) |
| Sept 2013 | - | -$5.36 M(>+9900.0%) | -$6.67 M(+407.1%) |
| June 2013 | - | -$8600.00(-99.3%) | -$1.32 M(+0.7%) |
| Mar 2013 | - | -$1.31 M(<-9900.0%) | -$1.31 M(<-9900.0%) |
| Dec 2012 | -$1.70 M | - | - |
| Aug 2010 | - | $0.00(0.0%) | $0.00(0.0%) |
| May 2010 | - | $0.00 | $0.00 |
FAQ
- What is Travere Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Travere Therapeutics?
- What is Travere Therapeutics annual CFI year-on-year change?
- What is Travere Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Travere Therapeutics?
- What is Travere Therapeutics quarterly CFI year-on-year change?
- What is Travere Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Travere Therapeutics?
- What is Travere Therapeutics TTM CFI year-on-year change?
What is Travere Therapeutics annual cash flow from investing activities?
The current annual CFI of TVTX is $55.78 M
What is the all time high annual CFI for Travere Therapeutics?
Travere Therapeutics all-time high annual cash flow from investing activities is $55.78 M
What is Travere Therapeutics annual CFI year-on-year change?
Over the past year, TVTX annual cash flow from investing activities has changed by +$88.33 M (+271.34%)
What is Travere Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of TVTX is $46.13 M
What is the all time high quarterly CFI for Travere Therapeutics?
Travere Therapeutics all-time high quarterly cash flow from investing activities is $133.32 M
What is Travere Therapeutics quarterly CFI year-on-year change?
Over the past year, TVTX quarterly cash flow from investing activities has changed by -$87.19 M (-65.40%)
What is Travere Therapeutics TTM cash flow from investing activities?
The current TTM CFI of TVTX is $162.68 M
What is the all time high TTM CFI for Travere Therapeutics?
Travere Therapeutics all-time high TTM cash flow from investing activities is $249.88 M
What is Travere Therapeutics TTM CFI year-on-year change?
Over the past year, TVTX TTM cash flow from investing activities has changed by +$126.66 M (+351.59%)